Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells

Arizona Cancer Center, University of Arizona, 1515 N. Campbell Avenue, Tucson, AZ 85724, USA.
Molecular Cancer Research (Impact Factor: 4.38). 02/2012; 10(3):392-400. DOI: 10.1158/1541-7786.MCR-11-0359
Source: PubMed


Oxidative protein folding in the endoplasmic reticulum (ER) requires strict regulation of redox homeostasis. Disruption of the lumenal redox balance induces an integrated ER stress response that is associated with reduced protein translation, increased chaperone activity, and ultimately cell death. Imexon is a small-molecule chemotherapeutic agent that has been shown to bind glutathione (GSH) and induce oxidative stress in tumor cells; however, the mechanism of cytotoxicity is not well understood. In this report, we investigate the effects of imexon on the integrated ER stress response in pancreatic carcinoma cells. Acute exposure to imexon induces an ER stress response characterized by accumulation of the oxidized form of the oxidoreductase Ero1α, phosphorylation of eIF2α, and inhibition of protein synthesis. An RNA interference chemosensitization screen identified the eukaryotic translation initiation factor eIF2B5 as a target that enhanced imexon-induced growth inhibition of MiaPaCa-2 pancreatic cancer cells, but did not significantly augment the effects of imexon on protein synthesis. Concurrent reduction of intracellular thiols with N-acetyl cysteine reversed imexon activity, however cotreatment with superoxide scavengers had no effect, suggesting thiol binding may be a primary component of the oxidative effects of imexon. Moreover, the data suggest that disruption of the redox balance in the ER is a potential therapeutic target.

Download full-text


Available from: Elena Sheveleva, Mar 20, 2014
1 Follower
58 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: NR4A1 (Nur77, TR3) is an orphan nuclear receptor that is overexpressed in pancreatic cancer and exhibits pro-oncogenic activity. RNA interference of NR4A1 expression in Panc-1 cells induced apoptosis and subsequent proteomic analysis revealed the induction of several markers of endoplasmic reticulum stress, including glucose-related protein 78 (GRP78), CCAAT/enhancer-binding protein-homologous protein (CHOP), and activating transcription factor-4 (ATF-4). Treatment of pancreatic cancer cells with the NR4A1 antagonist 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) gave similar results. Moreover, both NR4A1 knockdown and DIM-C-pPhOH induced reactive oxygen species (ROS), and induction of ROS and endoplasmic reticulum stress by these agents was attenuated after cotreatment with antioxidants. Manipulation of NR4A1 expression coupled with gene expression profiling identified a number of ROS metabolism transcripts regulated by NR4A1. Knockdown of one of these transcripts, thioredoxin domain containing 5 (TXNDC5), recapitulated the elevated ROS and endoplasmic reticulum stress; thus, demonstrating that NR4A1 regulates levels of endoplasmic reticulum stress and ROS in pancreatic cancer cells to facilitate cell proliferation and survival. Finally, inactivation of NR4A1 by knockdown or DIM-C-pPhOH decreased TXNDC5, resulting in activation of the ROS/endoplasmic reticulum stress and proapoptotic pathways. Implications: The NR4A1 receptor is pro-oncogenic, regulates the ROS/endoplasmic reticulum stress pathways, and inactivation of the receptor represents a novel pathway for inducing cell death in pancreatic cancer.
    Molecular Cancer Research 04/2014; 12(4):527-538. DOI:10.1158/1541-7786.MCR-13-0567 · 4.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoma cells are subject to higher levels of oxidative stress as compared to their normal counterparts and may be vulnerable to manipulations of the cellular redox balance. We therefore designed a phase II study of imexon (Amplimexon/NSC-714597), a pro-oxidant molecule, in patients with relapsed / refractory B-cell non-Hodgkin lymphomas (NHL). Imexon was administered at 1000 mg/m2 intravenously daily for 5 days in 21-day cycles. Gene expression analysis performed on pre-treatment tumor specimens included 13 transcripts used to generate a redox signature score, previously demonstrated to correlate with lymphoma prognosis. Twenty-two patients were enrolled having follicular (n=9), diffuse large B-cell (DLBCL) (n=5), mantle cell (n=3), transformed follicular (n=2), small lymphocytic (n=2) and Burkitt (n=1) lymphoma. The most common grade 3/4 adverse events were anemia (14%) and neutropenia (9%). The overall response rate was 30%: including responses in follicular lymphoma (4/9) and DLBCL (2/5). Gene expression analyses revealed CD68 and the redox related genes, GPX1 and SOD2, as well as a higher redox score to correlate with clinical responses. To our knowledge, this is the first demonstration of clinical activity with a pro-oxidant molecule in lymphoma. Pre-treatment markers of oxidative stress may identify patients likely to respond to this therapeutic approach. This study was registered at as #NCT01314014.
    Blood 07/2014; 124(8). DOI:10.1182/blood-2014-04-570044 · 10.45 Impact Factor